PTC Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
PTC Therapeutics, Inc. (PTCT) had Available-for-sale Securities, Amortized Cost Basis of $80.70 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-09
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $80.70M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $79.43M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $27.68M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $48.09M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-03-31 | $80.70M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $79.43M 10-Q · filed 2018-05-09 | |
| 2017-09-30 | $27.68M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $48.09M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $148.50M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $173.35M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $197.99M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $236.96M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $258.48M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $281.49M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $231.78M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $226.49M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $243.90M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $265.88M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $156.59M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $205.60M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $130.65M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $126.98M 10-K · filed 2015-03-02 | $126.98M 10-K · filed 2014-03-06 |
| 2013-09-30 | $133.22M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $11.58M 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |